Monograph of Adrenaline

Introduction

Definition and Overview

Adrenaline, also referred to as epinephrine, is a catecholamine produced primarily by the adrenal medulla and is released into systemic circulation in response to stressors such as hypoxia, hypoglycaemia, or allergic reactions. The drug form of adrenaline is employed in clinical settings for its potent sympathomimetic activity that augments cardiac output, vasoconstriction, bronchodilation, and metabolic stimulation. Its pharmacologic profile is characterised by a rapid onset of action and a short half‑life, making it indispensable in acute emergencies.

Historical Background

The discovery of adrenaline dates back to the late 19th century when the adrenal medulla was first identified as a source of a biologically active substance. Subsequent isolation and synthesis in the early 20th century enabled the development of adrenaline as a therapeutic agent. Its usage in anaphylactic shock, cardiac arrest, and bronchial obstruction has evolved through successive generations of formulations and delivery devices, culminating in modern intramuscular auto‑injectors and nebulised preparations.

Importance in Pharmacology and Medicine

Adrenaline occupies a pivotal role in emergency pharmacotherapy and is considered the first-line agent in several life‑threatening conditions. Its multimodal receptor activity on α₁, α₂, β₁, and β₂ adrenergic receptors underlies its therapeutic versatility. Understanding the pharmacologic nuances of adrenaline is essential for clinicians, pharmacists, and researchers involved in critical care, anesthesiology, emergency medicine, and respiratory therapy.

Learning Objectives

• Clarify the pharmacodynamic mechanisms that govern adrenaline’s actions on cardiovascular, respiratory, and metabolic systems.
• Describe the pharmacokinetic parameters influencing adrenaline’s absorption, distribution, metabolism, and elimination.
• Identify therapeutic indications, dosing regimens, and routes of administration used in contemporary practice.
• Assess factors that modify response to adrenaline, including receptor polymorphisms and concurrent medications.
• Apply knowledge to clinical case scenarios involving anaphylaxis, cardiac arrest, and severe asthma exacerbations.

Fundamental Principles

Core Concepts and Definitions

Adrenaline is a monoamine neurotransmitter that functions both as an endocrine hormone and a local autocrine/paracrine mediator. It exerts its effects by binding to G protein‑coupled adrenergic receptors, thereby modulating intracellular cyclic adenosine monophosphate (cAMP) pathways and ion channel activity. The term “adrenergic agonist” traditionally encompasses both endogenous catecholamines and exogenous drugs that stimulate these receptors.

Theoretical Foundations

Receptor pharmacology principles underpin adrenaline’s actions. Ligand binding induces conformational changes that activate or inhibit downstream signaling cascades. The affinity (K_D) and efficacy (E_max) of adrenaline at each receptor subtype dictate the magnitude of physiological responses. Competitive antagonism by β‑blockers, for instance, can attenuate the cardiac stimulatory effects of adrenaline, illustrating the importance of receptor pharmacodynamics in clinical outcomes.

Key Terminology

• α₁ and α₂ adrenergic receptors: mediate vasoconstriction and presynaptic inhibition.
• β₁ adrenergic receptors: primarily influence cardiac contractility and rate.
• β₂ adrenergic receptors: predominantly affect bronchodilation and vasodilation.
• Half‑life (t_1/2): the time required for plasma concentration to reduce by 50 %.
• Clearance (Cl): the volume of plasma from which the drug is completely removed per unit time.
• Area under the curve (AUC): integral of plasma concentration versus time, reflecting total drug exposure.

Detailed Explanation

Mechanisms of Action

Adrenaline activates α₁ receptors on vascular smooth muscle, triggering phospholipase C‑mediated release of intracellular calcium and consequent vasoconstriction. Concurrent β₁ activation increases myocardial oxygen demand and enhances cardiac output through positive inotropy and chronotropy. β₂ stimulation induces bronchodilation by relaxing bronchial smooth muscle, a critical effect in asthma and anaphylaxis. In metabolic tissues, α₂ receptor engagement reduces insulin secretion, elevating plasma glucose levels to meet acute energy demands.

Pharmacokinetic Relationships

The concentration–time profile of adrenaline follows first‑order elimination kinetics, described by the equation:

C(t) = C₀ × e⁻k_elt

where C₀ is the initial concentration and k_el is the elimination rate constant. The half‑life is calculated as:

t_1/2 = 0.693 ÷ k_el

Clearance and volume of distribution (V_d) are related through the equation:

k_el = Cl ÷ V_d

Thus, the AUC for a single intravenous dose equals:

AUC = Dose ÷ Cl

These relationships enable precise dosing calculations and prediction of drug exposure, especially when therapeutic drug monitoring is warranted.

Factors Influencing Pharmacokinetics and Pharmacodynamics

• Route of administration: Intramuscular or intravenous injections provide rapid onset; nebulised delivery yields slower absorption but sustained bronchodilation.
• Metabolic pathways: Catechol-O‑methyltransferase (COMT) and monoamine oxidase (MAO) mediate catecholamine degradation; polymorphisms can alter clearance rates.
• Patient age and comorbidities: Neonates and the elderly may exhibit reduced metabolic capacity, prolonging t_1/2.
• Concurrent medications: β‑blockers, MAO inhibitors, or other sympathomimetics can potentiate or mitigate adrenaline effects.
• Physiological states: Hypovolemia, sepsis, or shock increase sympathetic drive, potentially augmenting endogenous adrenaline levels and influencing exogenous dosing.

Clinical Significance

Relevance to Drug Therapy

Adrenaline is universally regarded as the cornerstone of resuscitative pharmacotherapy. Its dual action on cardiovascular and respiratory systems addresses the primary pathophysiologic derangements seen in anaphylaxis, cardiac arrest, and severe bronchospasm. The drug’s safety profile, when administered within recommended dosages, is well established, though careful titration is necessary in patients with pre‑existing cardiovascular disease.

Practical Applications

• Anaphylaxis: Intramuscular adrenaline at a dose of 0.3 mg (0.3 mg/kg for infants) is recommended within 1–2 minutes of symptom onset.
• Cardiac arrest: Intravenous adrenaline 1 mg every 3–5 minutes during advanced cardiac life support cycles.
• Severe asthma: Nebulised adrenaline 0.01 mg/mL or 0.05 mg/mL administered in 2 mL aliquots, repeated at 5–10 minute intervals.
• Hypotension in septic shock: Low‑dose infusion (0.05–0.2 µg/kg/min) may be employed as a vasopressor adjunct.

Clinical Examples

In a pediatric patient presenting with anaphylactic shock, the immediate intramuscular injection of adrenaline precipitates rapid haemodynamic stabilization, reducing the need for vasopressor support. Conversely, in a patient with a known β‑blocker overdose, the efficacy of adrenaline may be blunted, necessitating alternative agents such as glucagon to maintain cardiac output.

Clinical Applications/Examples

Case Scenario 1: Immediate Anaphylaxis in a 7‑Year‑Old

A child experiences urticaria, hypotension, and wheezing after a bee sting. The emergency team administers 0.1 mg intramuscular adrenaline. Within 3 minutes, blood pressure improves, and bronchospasm resolves. Subsequent monitoring shows a decline in serum tryptase, confirming the resolution of the allergic cascade. This scenario illustrates the time‑critical importance of intramuscular adrenaline in anaphylaxis.

Case Scenario 2: Cardiac Arrest During Surgery

During a laparoscopic procedure, a patient enters ventricular fibrillation. Advanced cardiac life support protocols are initiated, including 1 mg intravenous adrenaline every 5 minutes. Defibrillation and epinephrine administration lead to return of spontaneous circulation after 12 minutes. Post‑resuscitation care includes targeted temperature management and neuroprotection. This case demonstrates adrenaline’s role in sustaining perfusion during prolonged resuscitation efforts.

Case Scenario 3: Severe Asthma Exacerbation in the Emergency Department

An adult presents with severe wheeze and hypoxia. Nebulised adrenaline 0.01 mg/mL is delivered in 2 mL aliquots every 5 minutes. Repeat spirometry shows improvement in forced expiratory volume in 1 second (FEV₁) from 30 % to 65 % predicted. The patient is subsequently transitioned to oral corticosteroids and β‑agonist maintenance therapy. This example highlights adrenaline’s bronchial smooth‑muscle relaxation effect and synergy with other anti‑inflammatory agents.

Problem‑Solving Approach

1. Identify the primary pathophysiologic disturbance (e.g., hypovolaemia, bronchospasm).
2. Determine the optimal route and dose of adrenaline based on patient characteristics and clinical guidelines.
3. Monitor haemodynamic and respiratory parameters to assess response.
4. Adjust adjunctive therapies (e.g., antihistamines, corticosteroids) to sustain therapeutic gains.
5. Document outcomes and potential adverse events for future quality improvement.

Summary/Key Points

• Adrenaline is a potent α/β adrenergic agonist with rapid onset and short half‑life, central to emergency pharmacotherapy.
• Its pharmacodynamics involve vasoconstriction (α₁), cardiac stimulation (β₁), bronchodilation (β₂), and metabolic modulation (α₂).
• Key pharmacokinetic relationships: C(t) = C₀ × e⁻k_elt, t_1/2 = 0.693 ÷ k_el, AUC = Dose ÷ Cl.
• Clinical indications include anaphylaxis, cardiac arrest, severe asthma, and septic shock; dosing and routes are highly specific to each scenario.
• Factors such as age, comorbidities, concurrent medications, and genetic polymorphisms influence both efficacy and safety; vigilant monitoring is essential.
• Clinical pearls: intramuscular adrenaline remains the gold standard for anaphylaxis; intravenous adrenaline should be reserved for advanced cardiac life support; nebulised adrenaline is effective for severe bronchospasm but requires careful titration.

References

1. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
7. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
8. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.